Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2024. Details of the conferences appear below: Conference: Evercore ISI Diamonds in the Rough Webinar DayDate: Thursday, April 4, 2024 Time: 10:3
When it comes to deciding whether you should acquire penny stocks or not, the answer is no. Okay, so we’re done here, right? Of course, human nature being what it is, people are going to place wagers. Fundamentally, the issue with penny stocks is that this segment really blurs the line between investment and legalized gambling. More often than not, people lose their shirts in this corridor of the equities market. You’ve got to heed the warnings before you participate. Nevertheless, the one aspec
aTyr Pharma ( NASDAQ:LIFE ) Full Year 2023 Results Key Financial Results Net loss: US$50.4m (loss widened by 11% from...
aTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call Transcript March 14, 2024 aTyr Pharma, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and gentlemen, and welcome to the aTyr Pharma fourth quarter and full year 2023 conference […]
Q4 2023 aTyr Pharma Inc Earnings Call
G&A Expenses: General and administrative expenses were $13.0 million for the year. Net Loss: Reported a consolidated net loss of $50.4 million for the year. Corporate Updates: Continued progress in EFZO-FIT and EFZO-CONNECT studies, with enrollment completion expected in Q2 2024 for EFZO-FIT.
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD currently enrolling. Ended 2023 with $101.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00
Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDTSAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024. Manage
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Individual Patient EAP allows access to efzofitimod for patients who complete the Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis. Company initiating program based on blinded EFZO-FIT™ study investigator and patient participant feedback. SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today